Disposition kinetics, bioavailability and renal clearance of cefepime in calves.
The pharmacokinetics of cefepime were studied following intravenous and intramuscular administration of 6.5 mg/kg in four female Friesian calves. Following single intravenous administration, the serum concentration-time curves of cefepime were best fitted using a two-compartment open model. The elimination half-life (t(1/2)beta) was 2.38+/-0.16 h, volume of distribution at steady state (Vdss) was 0.21 +/- 0.01 L/kg, and total body clearance (ClB) was 1.1 +/- 0.08 ml/min per kg. Following intramuscular administration, the drug was rapidly absorbed with an absorption half-life (t(1/2)ab) of 0.29+/-0.02 h; maximum serum concentration (Cmax) of 21.7 +/- 1.1 microg/ml was attained after (Tmax) 1.1 +/- 0.08 h; and the drug was eliminated with an elimination half-life (t(1/2)el) of 3.02 +/- 0.18 h. The systemic bioavailability (F) after intramuscular administration of cefepime in calves was 95.7% +/- 7.44%. The in vitro serum protein-binding tendency was 10.5-16.7%. Following administration by both routes, the drug was excreted in high concentrations in urine for 24 h post administration.
Ismail
M M
MM
Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt. m_ism@hotmail.com
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D019540:Area Under Curve; D001682:Biological Availability; D002417:Cattle / Q000378:metabolism*; D000077723:Cefepime; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D003404:Creatinine / Q000097:blood / Q000652:urine; D018592:Cross-Over Studies; D005260:Female; D006207:Half-Life; D007273:Injections, Intramuscular / Q000662:veterinary; D007275:Injections, Intravenous / Q000662:veterinary; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077723:Cefepime; D003404:Creatinine
Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89-96
7587056
Tijdschr Diergeneeskd. 2000 Mar 1;125(5):147-52
10730339
Antimicrob Agents Chemother. 1985 Apr;27(4):574-7
3859244
J Pharmacokinet Biopharm. 1978 Apr;6(2):165-75
671222
J Vet Pharmacol Ther. 2001 Jun;24(3):187-92
11442796
Clin Infect Dis. 1992 Nov;15(5):824-39
1445981
Antimicrob Agents Chemother. 1985 Feb;27(2):207-16
3885849
Drug Metab Dispos. 1991 Jan-Feb;19(1):68-73
1673424
J Vet Med B Infect Dis Vet Public Health. 2000 Jun;47(5):329-35
10900823
Antimicrob Agents Chemother. 1985 May;27(5):679-82
3893316
Appl Microbiol. 1966 Mar;14(2):170-7
4959982
Clin Pharmacokinet. 1985 Mar-Apr;10 (2):101-43
3888488
J Clin Pharmacol. 1990 Oct;30(10):900-10
2229450
Vet Microbiol. 1986 Jul;12(2):109-18
3529604
J Antimicrob Chemother. 1993 Nov;32 Suppl B:103-15
8150753
Am J Vet Res. 1998 Apr;59(4):458-63
9563631
Antimicrob Agents Chemother. 1990 Oct;34(10):1932-7
2291658
Jpn J Antibiot. 1992 Aug;45(8):938-42
1433899
J S Afr Vet Assoc. 1981 Jun;52(2):99-104
6792356
J Antimicrob Chemother. 1995 Nov;36(5):757-71
8626256
Ann Pharmacother. 1999 Dec;33(12):1258-61
10630824
Antimicrob Agents Chemother. 1997 Aug;41(8):1783-7
9257761
Antimicrob Agents Chemother. 1990 Oct;34(10):1885-8
2291655
Am J Med. 1985 Aug 9;79(2A):2-13
3895915
Antimicrob Agents Chemother. 1992 Feb;36(2):453-7
1605609
Antimicrob Agents Chemother. 1987 May;31(5):799-804
3606078
Zentralbl Veterinarmed B. 1999 Dec;46(10):693-700
10676147
Chemotherapy. 1981;27 Suppl 1:42-6
7249794
Antimicrob Agents Chemother. 1992 Mar;36(3):552-7
1622165
Pharmacotherapy. 1993 Sep-Oct;13(5):465-70
8247913
Med Clin North Am. 1995 Jul;79(4):721-32
7791419
Pharmacotherapy. 1995 Jan-Feb;15(1 Pt 2):3S-8S
7753690